Decision on optimal combinatorinal Therapies in IMIDS using Systems approaches
Rheumatoid arthritis, like all the diseases addressed by the European DocTIS project, is an immune-mediated inflammatory disease (IMID). It’s a chronic inflammatory condition with unknown causes, which makes prevention unattainable. In 2019, the World Health Organization reported that 18 million
Immune-mediated inflammatory diseases (IMIDs) are complex and chronic conditions that significantly affect the quality of life of patients, often requiring continuous medical care. These diseases have a prevalence of between 5% to 7% in Western countries. These conditions are marked
An article in EU Research magazine, titled “Revolutionizing Treatment for Immune-Mediated Inflammatory Diseases”, highlights the techniques, results, trials, and potential impacts of DocTIS. The project aims to discover effective therapeutic strategies for immune-mediated inflammatory diseases (IMIDs) through drug combinations. The
Dr. Alejandro Gómez from Rheumatology Research Group at Vall d’Hebron Institut de Recerca and Dr. José Luis Andreu, Head of Rheumatology at Hospital Universitario Puerta del Hierro in Madrid, attended the European Congress of Rheumatology in Vienna to present findings
The scientific article “Interpretable Inflammation Landscape of Circulating Immune Cells”, recently published in bioRxiv, an open-access preprint repository for the biological sciences, leverages data from the DocTIS project. In this investigation, a comprehensive single-cell atlas was crafted, encompassing over two
Laura Jiménez and Davide Maspero from DocTIS partner Centro Nacional de Análisis Genómico (CNAG), recently attended the Innovations in Single Cell Omics conference (ISCO’24) in Barcelona, organized by Centre for Genomic Regulation (CRG), the Josep Carreras Leukaemia Research Institute and Instituto
On the occasion of the recent celebration of World Lupus Day, from the european project DocTIS we want to contribute by shedding light on one of its most common typologies, systemic lupus erythematosus. This Immune-Mediated Inflammatory disease, often poorly understood, is one of the
Inflammatory bowel disease (IBD) encompasses two chronic digestive disorders: ulcerative colitis and Crohn’s disease, impacting approximately 10 million individuals globally. Sadly, there is currently no cure, known cause, or widespread understanding of the daily pain and suffering bravely endured by
A partner of the DocTIS project, Vall d’Hebron Institut de Recerca, attended the 50th National Congress of the Spanish Society of Rheumatology in Maspalomas, Canary Islands, Spain. They delivered two significant presentations featuring contributions from DocTIS. Alejandro Gómez presented “Single
Lupus is an immune-mediated inflammatory disease that affects approximately 5 million people worldwide. Currently there is no cure, and only early diagnosis and expert care allow those who suffer from it to lead a normal life. One of its most